Abstract:Abstract While metastasis is the primary factor predicting poor outcomes in solid tumors, survival is lowest in patients initially diagnosed with a localized malignancy that then progresses to metastatic disease. Notably, nearly 25% of early-stage breast cancers (BCs) metastasize during treatment or following an initial positive response to therapeutic intervention. To define the molecular and cellular factors that contribute to metastatic progression of BC, we previously developed the Py230-C57Bl/6 syngeneic experimental metastasis model for interrogating mechanisms by which soluble factors condition premetastatic lung tissue to potentiate BC cell seeding/expansion. Using this model and the TCGA, we identified lipocalin-2 (Lcn2) as a molecular candidate that is upregulated in lung-tropic Py230 cells and other human triple-negative breast cancer (TNBC) cells, and that predicts poor outcomes in human BCs. While Lcn2 has been previously reported to mediate BC progression in genetically engineered mouse models, its mechanism(s) of action remain undefined. Here, we demonstrate that Py230 cell-secreted Lcn2 is necessary for optimal reprogramming of the premetastatic lung during metastatic progression. In agreement with these data, we defined a cell intrinsic role for Lcn2 in BC cell organoid assembly/invasion and expression of proinflammatory factors. To define BC cell extrinsic roles for Lcn2 in remodeling the premetastatic lung, we collected global transcriptome and single-cell spatial proteome data for lung tissue from C57Bl/6 mice systemically educated with mock media or media conditioned with Py8119 (Lcn2low) or Py230 (Lcn2hi) BC cells. Mice receiving Py230 conditioned media treatments were further divided between two groups – one receiving an isotype control IgG and the other receiving an Lcn2 immunoneutralizing antibody. Global transcriptome data was used to determine novel gene set enrichment signatures and clinically relevant interactomes – notable candidates predicted to cooperate with Lcn2 in decreasing patient survival were affiliated with cilia biogenesis and function. Single-cell spatial proteome data were analyzed for 28 different cell populations within the premetastatic lung. Interestingly, Py230 cell-derived Lcn2 did not affect the percentage of ciliated epithelial cells indicating that the global transcriptome data referenced above represent a real increase in expression of cilia-related genes and not an increase in cilia-positive cell types. Notably, we identified that Lcn2 increased the percentage of CD45neg/Despos mechanomodulatory cells and proliferating CD45pos/CD3pos/CD4neg/CD8pos cytotoxic T cells in the premetastatic lung. Taken together, these data define new targets around which new therapeutic strategies can be developed to improve BC patient outcomes. Citation Format: Joshua Gamez, Francesca Sanchez, Gabriela Ortiz-Soto, Jane Cox, Amir Gerami, Jonathan A. Kelber. Lipocalin-2 promotes breast cancer metastasis via tumor cell intrinsic and extrinsic mechanisms [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1495.

Lipocalin 2: a multifaceted modulator of human cancer.

Lipocalin 2 promotes breast cancer progression

LCN2: Versatile players in breast cancer

Lipocalin 2 negatively regulates cell proliferation and epithelial to mesenchymal transition through changing metabolic gene expression in colorectal cancer

Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion

Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy

Lipocalin-2 promotes breast cancer brain metastasis by enhancing tumor invasion and modulating brain microenvironment

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer

Lipocalin2 promotes cell proliferation and migration in ovarian cancer through activation of the ERK/GSK3β/β-catenin signaling pathway

LAMC2 Acts As a Novel Therapeutic Target of Cetuximab in Laryngeal Cancer.

Overview of the expression patterns and roles of Lipocalin 2 in the reproductive system

Bioinformatics and Experimental Approach Identify Lipocalin 2 As a Diagnostic and Prognostic Indicator for Lung Adenocarcinoma

An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment

Lipocalin2 Suppresses Metastasis of Colorectal Cancer by Attenuating NF-κB-dependent Activation of Snail and Epithelial Mesenchymal Transition

LCN2 promotes focal adhesion formation and invasion by stimulating Src activation.

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker

Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types

Lipocalin-2 is Associated With a Good Prognosis and Reversing Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma

Sex‐ and site‐specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort

Abstract 1495: Lipocalin-2 promotes breast cancer metastasis via tumor cell intrinsic and extrinsic mechanisms